The recent surge in investments into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and difficult drug development programs, has fueled what some are calling "High Stakeholder https://aishajafn811048.liberty-blog.com/40451345/high-stakeholder-pharma-the-risky-bet